Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2023-10-09 Capital/Financing Update
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Capital/Financing Update Classification · 96% confidence The document is a short press release dated October 9th, 2023, announcing an 'increase in the resources allocated to the liquidity contract' with a brokerage firm (Kepler Cheuvreux). It details the additional contribution (€50,000) and the current balance of shares and cash held under this contract. This action relates to maintaining market liquidity for the company's shares, which is a form of capital management or financing activity, but more specifically, it is a regulatory disclosure concerning market operations. Since it is a specific announcement about a financial arrangement (liquidity contract) and not a general regulatory filing (RNS), nor a major capital change (SHA/CAP), nor a director's dealing (DIRS), it fits best under Capital/Financing Update (CAP) as it directly impacts the structure supporting share trading, or potentially RNS as a general market announcement. Given the context of increasing resources for a liquidity contract, it is closely tied to capital structure support. However, looking at the definitions, 'Capital/Financing Update (CAP)' covers fundraising or capital structure changes. While this is a maintenance activity, it is a direct financial action related to the company's capital market presence. Since it is a specific, non-standard announcement, and not a core financial report, RNS is a strong candidate. But because it explicitly details a financial resource allocation (cash/shares) related to market support, CAP is slightly more precise than the general RNS fallback. Given the short length and announcement nature, I will check the RPA rule. It is not announcing the publication of a major report (like 10-K or IR), but rather an operational update. Therefore, CAP or RNS are the best fits. I will select CAP as it is a specific financial/capital market operation disclosure.
2023-10-09 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital" and explicitly references regulatory articles from the French AMF (Autorité des Marchés Financiers) concerning the disclosure of total voting rights and share capital as of a specific date (September 30, 2023). This type of periodic disclosure, which reports on the number of shares and voting rights, is a specific regulatory requirement. While it is a regulatory filing, it does not fit the general 'RNS' category as well as it fits a category related to capital structure or shareholder information. However, none of the provided codes perfectly match a 'Total Voting Rights' disclosure. The closest related concepts are 'Share Issue/Capital Change' (SHA) or 'Major Shareholding Notification' (MRQ), but this is a routine monthly update on the existing structure, not a change event or a major shareholder crossing a threshold. Given the nature of the data (total shares and voting rights) and the regulatory context, it is a mandatory disclosure. Since there is no specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory announcement, the most appropriate fallback category that covers mandatory regulatory disclosures not covered elsewhere is 'RNS' (Regulatory Filings). It is not an ER, IR, 10-K, or a specific corporate action like DIV or SHA, but a mandatory periodic report on capital structure components.
2023-10-06 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) and provides a table detailing the total number of shares and voting rights as of a specific date (30/09/2023). This type of mandatory periodic disclosure regarding the capital structure and voting rights is a specific regulatory filing, often related to share capital changes or major holdings, but it does not fit perfectly into the standard US SEC forms (like 10-K, ER, or DIV). Among the provided definitions, this content most closely aligns with a notification of changes in share capital or significant ownership structure. Since it is a formal, periodic regulatory disclosure concerning the number of shares and voting rights, it is best classified as a notification related to share capital changes or a general regulatory filing. Given the options, 'Share Issue/Capital Change' (SHA) covers changes in the capital structure, and 'Major Shareholding Notification' (MRQ) covers changes in ownership thresholds. However, this specific French filing (often referred to as a 'Declaration mensuelle') is a mandatory disclosure of the total share count, which is a prerequisite for tracking major holdings or capital changes. Since it is a formal regulatory announcement detailing the current share count, and it is not a dividend notice (DIV), director dealing (DIRS), or a general earnings release (ER), it falls under the category of capital structure updates or a general regulatory filing. Because it explicitly details the total number of shares and voting rights, it is a direct update on the capital structure, making SHA a strong candidate, or RNS as a general regulatory filing. Given the specific nature of reporting total voting rights, which is often linked to capital structure updates, I will lean towards the most specific relevant category that isn't explicitly covered by other options. Since it is a formal, periodic regulatory disclosure about the total number of shares and voting rights, it is a type of capital structure update. If a more specific 'Capital Structure Disclosure' existed, it would fit there. Between SHA (Share Issue/Capital Change) and RNS (Regulatory Filings), SHA is more descriptive of the content (total shares/voting rights). However, in many contexts, these monthly voting rights reports are treated as general regulatory updates. Let's re-evaluate the definitions. It is not a transaction in own shares (POS), nor a general share issue (SHA) unless a change occurred. It is a mandatory disclosure of the current state. This is a classic 'Regulatory Filing' (RNS) or potentially related to 'Major Shareholding Notification' (MRQ) if thresholds were crossed, but here it's a routine monthly report. I will classify it as RNS as the most appropriate fallback for a mandatory, non-standardized regulatory report that isn't an earnings release or financial report itself.
2023-10-06 French
Inside Information / Other news releases
Regulatory Filings Classification · 94% confidence The document is a press release titled "MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)". It details the acceptance of abstracts for poster presentations at a scientific conference, including titles and abstract numbers. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is an announcement about participation in an external event, which often falls under general investor relations or regulatory announcements. Since it is a specific announcement about scientific data presentation rather than a general regulatory filing (RNS) or a standard investor presentation (IP), and given the options, it best fits as a general announcement related to investor/company activity. However, since it is an announcement of scientific data being presented externally, and not a formal presentation document itself, the most appropriate category among the choices that covers specific corporate updates that aren't strictly financial or governance is often the general Regulatory Filings (RNS) if no better fit exists, or potentially Investor Presentation (IP) if it were the presentation slides. Given the content is an announcement *about* presentations, and not the presentation itself, RNS is the safest fallback for a specific, non-standard corporate update. Alternatively, since it is an announcement intended for investors about scientific progress, it could be argued as a type of Investor Presentation announcement, but RNS is the standard catch-all for press releases announcing specific, non-standard corporate events.
2023-09-27 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release from MaaT Pharma announcing the selection of two posters for presentation at the 38th annual conference of the Society for Immunotherapy of Cancer (SITC). It details the content of the posters (non-clinical data on MaaT03X) and provides context about the scientific findings. This type of announcement, focusing on scientific data presentation at an external industry event, is typically classified as an Investor Presentation (IP) or a general regulatory/corporate update. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a management change (MANG) or dividend notice (DIV), and it specifically details scientific/clinical updates intended for investors and the scientific community, 'Investor Presentation' (IP) is the most fitting category, as these announcements often precede or accompany detailed investor briefings or presentations. It is not a Report Publication Announcement (RPA) because it is announcing the *content* to be presented, not just the publication of a formal company report.
2023-09-27 French
Rapport Financier Semestriel
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2023' (Half-Year Financial Report as of June 30, 2023) for MaaT Pharma SA. It contains a comprehensive summary, management report (Rapport d'activité), interim financial statements (Etats financiers semestriels résumés), and an audit report reference. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H2 2023
2023-09-27 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.